Cresco Labs (CRLBF) Debt Ratio (2019 - 2026)

Cresco Labs' (CRLBF) quarterly Debt Ratio came in at 0.36 in Q1 2026, little changed on a QoQ basis from 0.36 in Q4 2025.

Cresco Labs (CRLBF) Debt Ratio (2019 - 2026) Analysis & Trends

Cresco Labs (CRLBF) has 7 years of Debt Ratio data on file, last reported at 0.36 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.36 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.36 (changed N/A YoY) and the FY2025 annual result came in at 0.36, up 3958.68% from the prior year.
Debt Ratio was little changed at 0.36 in Q1 2026, from 0.36 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.38 in Q4 2023 to a low of 0.01 in Q4 2022.
A 5-year average of 0.27 and a median of 0.36 in 2026 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2023 — Debt Ratio surged 5311.87% — and 2024, when it tumbled 97.65%.
Tracing CRLBF's Debt Ratio over 5 years: stood at 0.01 in 2022, then surged by 5311.87% to 0.38 in 2023, then plunged by 97.65% to 0.01 in 2024, then surged by 3958.68% to 0.36 in 2025, then increased by 0.15% to 0.36 in 2026.
The last three Debt Ratio figures came in at 0.36 (Q1 2026), 0.36 (Q4 2025), and 0.01 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn	0.42
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn	0.32
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn	-
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	0.12
10	Cresco Labs	290.46 Mn	226.34 Mn	86.95 Mn	0.33

Download Data